Provided by Tiger Trade Technology Pte. Ltd.

Neumora Therapeutics, Inc.

1.63
+0.11507.59%
Post-market: 1.630.00000.00%19:38 EDT
Volume:499.11K
Turnover:798.29K
Market Cap:306.44M
PE:-1.33
High:1.64
Open:1.51
Low:1.51
Close:1.52
52wk High:3.65
52wk Low:0.8302
Shares:188.00M
Float Shares:116.00M
Volume Ratio:0.45
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2237
EPS(LYR):-1.4501
ROE:-187.11%
ROA:-73.85%
PB:6.88
PE(LYR):-1.12

Loading ...

Neumora Therapeutics Posts Corporate Presentation on Neuroscience Drug Development Pipeline

Reuters
·
Jul 27

Neumora Plans Nmra-215 Clinical Trial in 2026 After Favorable Toxicology Results

Reuters
·
Jul 27

Neumora Therapeutics Reports Favorable Nmra-215 Toxicology Results with Planned Clinical Advancement in 2026

THOMSON REUTERS
·
Jul 27

Neumora Therapeutics - Repeat 13-Week Rat Toxicology Study Shows no Unexpected in-Life Adverse Findings

THOMSON REUTERS
·
Jul 27

Neumora Therapeutics - Anticipates Initiating Clinical Study for Nmra-215 in 2026

THOMSON REUTERS
·
Jul 27

Neumora Therapeutics - Plans to Submit Ind Application for Nmra-215 in Q4 2026

THOMSON REUTERS
·
Jul 27

Neumora Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 13

RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 13

Neumora Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
Jun 19

Mizuho Adjusts Price Target on Neumora Therapeutics to $4 From $6, Maintains Outperform Rating

MT Newswires Live
·
Jun 18

Neumora Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 16

Neumora Therapeutics price target lowered to $7 from $18 at H.C. Wainwright

TIPRANKS
·
Jun 16

Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102

TIPRANKS
·
Jun 16

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA) and Amgen (AMGN)

TIPRANKS
·
Jun 16

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex

Reuters
·
Jun 16

Sector Update: Healthcare

MT Newswires Live
·
Jun 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

Neumora Halts Navacaprant Development After Phase 3 Depression Trials Miss Primary Endpoints; Shares Fall Pre-Bell

MT Newswires Live
·
Jun 15

Neumora Therapeutics Scraps Lead Asset Navacaprant After Study Failures

Dow Jones
·
Jun 15

Neumora Therapeutics Shares Drop 48% Premarket After Co to Stop Development of Its Depression Drug

THOMSON REUTERS
·
Jun 15